Further studies of more specific compounds and exploration into combinations of clinical drugs that targeting SPHK1 and S1PR3 can offer aid in explaining their mechanism and exploring the treatment possibilities in LAM and other TSC2-related diseases. The gene discussed is SPHK1; the disease is lymphangioleiomyomatosis.